Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy.

Muz B, Azab F, Fiala M, King J, Kohnen D, Fogler WE, Smith T, Magnani JL, Vij R, Azab AK.

Blood Cancer J. 2019 Aug 20;9(9):68. doi: 10.1038/s41408-019-0227-3. No abstract available.

2.

Bone vascular niche E-selectin induces mesenchymal-epithelial transition and Wnt activation in cancer cells to promote bone metastasis.

Esposito M, Mondal N, Greco TM, Wei Y, Spadazzi C, Lin SC, Zheng H, Cheung C, Magnani JL, Lin SH, Cristea IM, Sackstein R, Kang Y.

Nat Cell Biol. 2019 May;21(5):627-639. doi: 10.1038/s41556-019-0309-2. Epub 2019 Apr 15.

3.

Determination of Glycolipid Ligands of Carbohydrate-Binding Proteins Directly on Thin Layer Chromatograms.

Magnani JL.

Methods Mol Biol. 2018;1804:419-427. doi: 10.1007/978-1-4939-8552-4_21.

PMID:
29926422
4.

P- and E-selectin receptor antagonism prevents human leukocyte adhesion to activated porcine endothelial monolayers and attenuates porcine endothelial damage.

Laird CT, Hassanein W, O'Neill NA, French BM, Cheng X, Fogler WE, Magnani JL, Parsell D, Cimeno A, Phelps CJ, Ayares D, Burdorf L, Azimzadeh AM, Pierson RN 3rd.

Xenotransplantation. 2018 Mar;25(2):e12381. doi: 10.1111/xen.12381. Epub 2018 Jan 23.

PMID:
29359469
5.

Selectin catch-bonds mechanotransduce integrin activation and neutrophil arrest on inflamed endothelium under shear flow.

Morikis VA, Chase S, Wun T, Chaikof EL, Magnani JL, Simon SI.

Blood. 2017 Nov 9;130(19):2101-2110. doi: 10.1182/blood-2017-05-783027. Epub 2017 Aug 15.

6.

E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271.

Natoni A, Smith TAG, Keane N, McEllistrim C, Connolly C, Jha A, Andrulis M, Ellert E, Raab MS, Glavey SV, Kirkham-McCarthy L, Kumar SK, Locatelli-Hoops SC, Oliva I, Fogler WE, Magnani JL, O'Dwyer ME.

Leukemia. 2017 Dec;31(12):2642-2651. doi: 10.1038/leu.2017.123. Epub 2017 Apr 25.

7.

E-selectin inhibition with GMI-1271 decreases venous thrombosis without profoundly affecting tail vein bleeding in a mouse model.

Culmer DL, Dunbar ML, Hawley AE, Sood S, Sigler RE, Henke PK, Wakefield TW, Magnani JL, Myers DD Jr.

Thromb Haemost. 2017 Jun 2;117(6):1171-1181. doi: 10.1160/TH16-04-0323. Epub 2017 Mar 16.

PMID:
28300869
8.

E-Selectin Inhibition Mitigates Splenic HSC Activation and Myelopoiesis in Hypercholesterolemic Mice With Myocardial Infarction.

Dutta P, Hoyer FF, Sun Y, Iwamoto Y, Tricot B, Weissleder R, Magnani JL, Swirski FK, Nahrendorf M.

Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):1802-8. doi: 10.1161/ATVBAHA.116.307519. Epub 2016 Jul 28.

9.

Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use.

Telen MJ, Wun T, McCavit TL, De Castro LM, Krishnamurti L, Lanzkron S, Hsu LL, Smith WR, Rhee S, Magnani JL, Thackray H.

Blood. 2015 Apr 23;125(17):2656-64. doi: 10.1182/blood-2014-06-583351. Epub 2015 Mar 2.

10.

Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia.

Wun T, Styles L, DeCastro L, Telen MJ, Kuypers F, Cheung A, Kramer W, Flanner H, Rhee S, Magnani JL, Thackray H.

PLoS One. 2014 Jul 2;9(7):e101301. doi: 10.1371/journal.pone.0101301. eCollection 2014. Erratum in: PLoS One. 2014;9(10):e111690.

11.

Implications of the E-selectin S128R mutation for drug discovery.

Preston RC, Rabbani S, Binder FP, Moes S, Magnani JL, Ernst B.

Glycobiology. 2014 Jul;24(7):592-601. doi: 10.1093/glycob/cwu026. Epub 2014 Mar 31.

12.

Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9.

Diamandis EP, Bast RC Jr, Gold P, Chu TM, Magnani JL.

Clin Chem. 2013 Jan;59(1):22-31. doi: 10.1373/clinchem.2012.187047. Epub 2012 Nov 30. No abstract available.

13.

Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance.

Winkler IG, Barbier V, Nowlan B, Jacobsen RN, Forristal CE, Patton JT, Magnani JL, Lévesque JP.

Nat Med. 2012 Nov;18(11):1651-7. doi: 10.1038/nm.2969. Epub 2012 Oct 21.

PMID:
23086476
14.

E-selectin ligands as mechanosensitive receptors on neutrophils in health and disease.

Chase SD, Magnani JL, Simon SI.

Ann Biomed Eng. 2012 Apr;40(4):849-59. doi: 10.1007/s10439-011-0507-y. Epub 2012 Jan 24. Review.

15.

Pre-organization of the core structure of E-selectin antagonists.

Schwizer D, Patton JT, Cutting B, Smieško M, Wagner B, Kato A, Weckerle C, Binder FP, Rabbani S, Schwardt O, Magnani JL, Ernst B.

Chemistry. 2012 Jan 27;18(5):1342-51. doi: 10.1002/chem.201102884. Epub 2011 Dec 30.

PMID:
22213563
16.

P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.

Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, Patton JT, Maiso P, Monrose V, Sacco A, Ngo HT, Flores LM, Lin CP, Magnani JL, Kung AL, Letai A, Carrasco R, Roccaro AM, Ghobrial IM.

Blood. 2012 Feb 9;119(6):1468-78. doi: 10.1182/blood-2011-07-368050. Epub 2011 Nov 16.

17.

GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.

Chang J, Patton JT, Sarkar A, Ernst B, Magnani JL, Frenette PS.

Blood. 2010 Sep 9;116(10):1779-86. doi: 10.1182/blood-2009-12-260513. Epub 2010 May 27.

18.

Glycomimetic drugs--a new source of therapeutic opportunities.

Magnani JL, Ernst B.

Discov Med. 2009 Dec;8(43):247-52.

19.

Probing the carbohydrate recognition domain of E-selectin: the importance of the acid orientation in sLex mimetics.

Titz A, Patton J, Smiesko M, Radic Z, Schwardt O, Magnani JL, Ernst B.

Bioorg Med Chem. 2010 Jan 1;18(1):19-27. doi: 10.1016/j.bmc.2009.11.024. Epub 2009 Nov 13.

PMID:
19948406
20.

From carbohydrate leads to glycomimetic drugs.

Ernst B, Magnani JL.

Nat Rev Drug Discov. 2009 Aug;8(8):661-77. doi: 10.1038/nrd2852. Epub 2009 Jul 24. Review.

PMID:
19629075
21.

Comparative epitope mapping with saturation transfer difference NMR of sialyl Lewis(a) compounds and derivatives bound to a monoclonal antibody.

Herfurth L, Ernst B, Wagner B, Ricklin D, Strasser DS, Magnani JL, Benie AJ, Peters T.

J Med Chem. 2005 Nov 3;48(22):6879-86.

PMID:
16250646
22.

Quinic acid derivatives as sialyl Lewis(x)-mimicking selectin inhibitors: design, synthesis, and crystal structure in complex with E-selectin.

Kaila N, Somers WS, Thomas BE, Thakker P, Janz K, DeBernardo S, Tam S, Moore WJ, Yang R, Wrona W, Bedard PW, Crommie D, Keith JC Jr, Tsao DH, Alvarez JC, Ni H, Marchese E, Patton JT, Magnani JL, Camphausen RT.

J Med Chem. 2005 Jun 30;48(13):4346-57.

PMID:
15974587
23.

The discovery, biology, and drug development of sialyl Lea and sialyl Lex.

Magnani JL.

Arch Biochem Biophys. 2004 Jun 15;426(2):122-31. Review.

PMID:
15158662
24.

Nanomolar E-selectin inhibitors: 700-fold potentiation of affinity by multivalent ligand presentation.

Thoma G, Duthaler RO, Magnani JL, Patton JT.

J Am Chem Soc. 2001 Oct 17;123(41):10113-4. No abstract available.

PMID:
11592897
25.

A Readily Available, Highly Potent E-Selectin Antagonist.

Thoma G, Bänteli R, Jahnke W, Magnani JL, Patton JT.

Angew Chem Int Ed Engl. 2001 Oct 1;40(19):3644-3647. No abstract available.

PMID:
11592208
26.

Preorganization of the Bioactive Conformation of Sialyl Lewis(X) Analogues Correlates with Their Affinity to E-Selectin.

Thoma G, Magnani JL, Patton JT, Ernst B, Jahnke W.

Angew Chem Int Ed Engl. 2001 May 18;40(10):1941-1945. No abstract available.

PMID:
11385680
27.

Synthesis and biological evaluation of a sialyl Lewis X mimic with significantly improved E-selectin inhibition.

Thoma G, Magnani JL, Patton JT.

Bioorg Med Chem Lett. 2001 Apr 9;11(7):923-5.

PMID:
11294392
28.

Synthesis and biological evaluation of a potent E-selectin antagonist.

Thoma G, Kinzy W, Bruns C, Patton JT, Magnani JL, Bänteli R.

J Med Chem. 1999 Nov 18;42(23):4909-13.

PMID:
10579852
29.

Application of homonuclear 3D NMR experiments and 1D analogs to study the conformation of sialyl Lewis(x) bound to E-selectin.

Scheffler K, Brisson JR, Weisemann R, Magnani JL, Wong WT, Ernst B, Peters T.

J Biomol NMR. 1997 Jun;9(4):423-36.

PMID:
9255946
31.

Glycolipids carrying Le(y) are preferentially expressed on small-cell lung cancer cells as detected by the monoclonal antibody MLuC1.

Leoni F, Colnaghi MI, Canevari S, Ménard S, Colzani E, Facheris P, Figini M, Miotti S, Magnani JL.

Int J Cancer. 1992 May 8;51(2):225-31.

PMID:
1373704
32.

Characterization of a series of novel fucose-containing glycosphingolipid immunogens from eggs of Schistosoma mansoni.

Levery SB, Weiss JB, Salyan ME, Roberts CE, Hakomori S, Magnani JL, Strand M.

J Biol Chem. 1992 Mar 15;267(8):5542-51.

33.

Rational targets for the early detection of lung cancer.

Mulshine JL, Linnoila RI, Jensen SM, Magnani JL, Tockman MS, Gupta PK, Scott FS, Avis I, Quinn K, Birrer MJ, et al.

J Natl Cancer Inst Monogr. 1992;(13):183-90. Review.

PMID:
1389692
34.

The tumor markers, sialyl Le(a) and sialyl Le(x) bind ELAM-1.

Magnani JL.

Glycobiology. 1991 Sep;1(4):318-20. No abstract available.

PMID:
1726465
35.

A carbohydrate domain common to both sialyl Le(a) and sialyl Le(X) is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1.

Berg EL, Robinson MK, Mansson O, Butcher EC, Magnani JL.

J Biol Chem. 1991 Aug 15;266(23):14869-72.

36.

Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas.

Pastan I, Lovelace ET, Gallo MG, Rutherford AV, Magnani JL, Willingham MC.

Cancer Res. 1991 Jul 15;51(14):3781-7.

37.

Antibody 624H12, which detects lung cancer at early stages, recognizes a sugar sequence in the glycosphingolipid difucosylneolactonorhexaosylceramide (V3FucIII3FunLc6Cer).

Kyogashima M, Mulshine J, Linnoila RI, Jensen S, Magnani JL, Nudelman E, Hakomori S, Ginsburg V.

Arch Biochem Biophys. 1989 Nov 15;275(1):309-14.

PMID:
2554809
38.
39.

Monoclonal antibodies reactive with mucin glycoproteins found in sera from breast cancer patients.

Linsley PS, Brown JP, Magnani JL, Horn D.

Cancer Res. 1988 Apr 15;48(8):2138-48.

40.

The antitumor monoclonal antibody MOv2 recognizes the Lewis A hapten.

Leoni F, Magnani JL, Miotti S, Canevari S, Pasquali M, Sonnino S, Colnaghi MI.

Hybridoma. 1988 Apr;7(2):129-39.

PMID:
3372000
41.

Ewing's sarcoma is an undifferentiated neuroectodermal tumor.

Cavazzana AO, Magnani JL, Ross RA, Miser J, Triche TJ.

Prog Clin Biol Res. 1988;271:487-98. No abstract available.

PMID:
2900513
42.
44.

Mouse and rat monoclonal antibodies directed against carbohydrates.

Magnani JL.

Methods Enzymol. 1987;138:484-91. No abstract available.

PMID:
3600341
45.

Immunostaining free oligosaccharides directly on thin-layer chromatograms.

Magnani JL.

Methods Enzymol. 1987;138:208-12. No abstract available.

PMID:
3600322
46.

Antibodies against cell surface carbohydrates: determination of antigen structure.

Magnani JL, Spitalnik SL, Ginsburg V.

Methods Enzymol. 1987;138:195-207. No abstract available.

PMID:
2439871
47.

Carbohydrate sequences detected by murine monoclonal antibodies.

Magnani JL.

Chem Phys Lipids. 1986 Dec 15;42(1-3):65-74. Review.

PMID:
2435425
48.

A monoclonal antibody against meningococcus group B polysaccharides distinguishes embryonic from adult N-CAM.

Rougon G, Dubois C, Buckley N, Magnani JL, Zollinger W.

J Cell Biol. 1986 Dec;103(6 Pt 1):2429-37.

49.

Glycolipid antigen expression in human lung cancer.

Spitalnik SL, Spitalnik PF, Dubois C, Mulshine J, Magnani JL, Cuttitta F, Civin CI, Minna JD, Ginsburg V.

Cancer Res. 1986 Sep;46(9):4751-5.

50.

Supplemental Content

Loading ...
Support Center